Krystal Biotech, Inc. (BIT:1KRYS)

Italy flag Italy · Delayed Price · Currency is EUR
118.75
-2.45 (-2.02%)
At close: Jun 27, 2025, 5:30 PM CET
-10.88%
Market Cap 3.47B
Revenue (ttm) 308.51M
Net Income (ttm) 114.69M
Shares Out n/a
EPS (ttm) 3.84
PE Ratio 30.25
Forward PE 18.92
Dividend n/a
Ex-Dividend Date n/a
Volume 15
Average Volume 26
Open 126.05
Previous Close 121.20
Day's Range 118.75 - 126.05
52-Week Range 118.75 - 133.25
Beta n/a
RSI n/a
Earnings Date Aug 4, 2025

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 275
Stock Exchange Borsa Italiana
Ticker Symbol 1KRYS
Full Company Profile

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Financial numbers in USD Financial Statements

News

There is no news available yet.